Controlled release of a model vaccine by nanoporous ceramic microneedle arrays

M.A. Boks, W.W.J. Unger, S. Engels, M. Ambrosini, Y. Van Kooyk, R. Luttge

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.

Original languageEnglish
Article number14977
Pages (from-to)375-383
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume491
Issue number1-2
DOIs
Publication statusPublished - 14 Jul 2015

Fingerprint

Ceramics
Vaccines
T-Lymphocytes
Vaccination
Syringes
Skin
Needles
Intradermal Injections
Peptides
Langerhans Cells
Anti-Idiotypic Antibodies
Immunity
B-Lymphocytes
Technology
Injections

Keywords

  • (Anti-tumor) CD8 T cell response
  • (Trans)dermal drug delivery
  • Ceramic nanoporous microneedles
  • Human skin
  • Vaccine delivery

Cite this

Boks, M.A. ; Unger, W.W.J. ; Engels, S. ; Ambrosini, M. ; Van Kooyk, Y. ; Luttge, R. / Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. In: International Journal of Pharmaceutics. 2015 ; Vol. 491, No. 1-2. pp. 375-383.
@article{73a6ba178ea2477883c9f1726115e5c3,
title = "Controlled release of a model vaccine by nanoporous ceramic microneedle arrays",
abstract = "Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.",
keywords = "(Anti-tumor) CD8 T cell response, (Trans)dermal drug delivery, Ceramic nanoporous microneedles, Human skin, Vaccine delivery",
author = "M.A. Boks and W.W.J. Unger and S. Engels and M. Ambrosini and {Van Kooyk}, Y. and R. Luttge",
year = "2015",
month = "7",
day = "14",
doi = "10.1016/j.ijpharm.2015.06.025",
language = "English",
volume = "491",
pages = "375--383",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

Controlled release of a model vaccine by nanoporous ceramic microneedle arrays. / Boks, M.A.; Unger, W.W.J.; Engels, S.; Ambrosini, M.; Van Kooyk, Y.; Luttge, R.

In: International Journal of Pharmaceutics, Vol. 491, No. 1-2, 14977, 14.07.2015, p. 375-383.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Controlled release of a model vaccine by nanoporous ceramic microneedle arrays

AU - Boks, M.A.

AU - Unger, W.W.J.

AU - Engels, S.

AU - Ambrosini, M.

AU - Van Kooyk, Y.

AU - Luttge, R.

PY - 2015/7/14

Y1 - 2015/7/14

N2 - Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.

AB - Abstract Current vaccination technology can advance from the use of novel ceramic nanoporous microneedle arrays (npMNA), where the material serves as a storage reservoir for vaccines. Moreover, npMNA will enhance vaccine efficacy by more precisely reaching skin dendritic cells, the kickstarters of T and B cell immunity. In the present study we assessed the efficacy of vaccination using npMNAs by in vivo application of OVA257-264 peptides mixed with agonistic anti-CD40 antibodies as adjuvant. The induction of OVA-specific CD8+ T cells via npMNA was comparable with the frequency induced via intradermal injection using needle-syringe. However, only when expanding the vaccination area by using two npMNAs the frequencies of induced IFN-γ-specific effector CD8+ T cells were comparable with those induced via needle-syringe injection. Analysis of vaccine release from npMNA in a human ex vivo skin explant model revealed that OVA257-264 peptides were indeed delivered intradermal, and release also increased by prolonging the npMNA application time on the human skin. Together, our studies demonstrate the potential of npMNA for vaccine delivery in human skin and in vivo induction of CD8+ effector T cell responses.

KW - (Anti-tumor) CD8 T cell response

KW - (Trans)dermal drug delivery

KW - Ceramic nanoporous microneedles

KW - Human skin

KW - Vaccine delivery

UR - http://www.scopus.com/inward/record.url?scp=84937597799&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2015.06.025

DO - 10.1016/j.ijpharm.2015.06.025

M3 - Article

C2 - 26116016

AN - SCOPUS:84937597799

VL - 491

SP - 375

EP - 383

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

M1 - 14977

ER -